Prosecution Insights
Last updated: October 04, 2026
Application No. 18/593,290

Mechanism for Bioavailable Delivery of Electrolytes

Final Rejection §112
Filed
Mar 01, 2024
Priority
Mar 03, 2023 — provisional 63/449,720
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Inlyte LLC
OA Round
2 (Final)
85%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
81%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allowance Rate
1348 granted / 1589 resolved
+24.8% vs TC avg
Minimal -4% lift
Without
With
+-4.0%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
46 currently pending
Career history
1625
Total Applications
across all art units

Statute-Specific Performance

§101
5.2%
-34.8% vs TC avg
§103
16.5%
-23.5% vs TC avg
§102
19.7%
-20.3% vs TC avg
§112
44.7%
+4.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1589 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Shift of Invention The general policy of the USPTO is that applicants are not permitted to shift to claim another invention after an election is made and an Office Action on the merits is made on the elected invention (MPEP 819). Newly added claims 13-23 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: new independent claim 13, and its associated dependent claims, claims 14-23, are directed to a newly presented method of creating a water-soluble powdered proliposome which is independent and distinct from the method(s) of the previously pending claims, and is, in fact, much broader in scope. Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, newly added claims 13-23 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03. Information Disclosure Statement The lined-through listing is both incomplete and of improper format. (See MPEP 707.05(e)(IV) for examples of proper citation format for electronic documents.) Claim Objections Withdrawn The objections to claims 1 and 12, outlined in the previous Office Action, have been overcome by inventor’s amendment. The amendment corrects the claim texts as appropriate. Claim Objections, NEW Claim 6 is objected to because of the following informalities: for grammatical reasons, in the second line of the claim, the definite article the which appears before the term drying should be deleted. Appropriate correction is required. Inventor’s assistance is again respectfully requested in correcting any other minor grammatical and/or spelling errors which may be present in the claim set. 112(b) Rejections Withdrawn The rejections of claims 1-7, 11 and 12 under 35 USC 112(b) or 35 USC 112 (pre-AIA ), second paragraph, outlined in the previous Office Action, have been overcome by inventor’s amendment. With respect to claims 1-5, 7, 11 and 12, the amendment clarifies the claims as appropriate. With respect to claim 6 (indefinite from indefinite), the rejection is moot. Claim Rejections - 35 USC § 112(b), NEW The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 4 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. There is insufficient antecedent basis for the limitation “…CBD, CBG…” in the claim. Clarification is in order. 112(d) Rejections Withdrawn The rejection of claim 7 under 35 USC 112(d) or 35 USC 112 (pre-AIA ), fourth paragraph, outlined in the previous Office Action, has been overcome by inventor’s amendment. The amendment rewrites the claim as an independent claim. Claim Rejections - 35 USC § 112(d), NEW The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 11 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, fourth paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. In the present instance, the claim fails to further limit the subject matter of the claim upon which it depends. Independent claim 1, the claim from which claim 11 immediately depends, already teaches that both the stated homogenizing steps are performed at between 10,000 to 20,000 psi. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. The examiner respectfully suggests canceling the claim. Claim 12 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, fourth paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. In the present instance, the claim fails to further limit the subject matter of the claim upon which it depends. Claim 12 actually expands the scope of the subject matter of the claim upon which it depends (dependent claim 3), since the claim which claim 3 depends upon, independent claim 1, only teaches the utilization of Epsom salt. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claim 1-3, 5 and 7 are allowed for reasons of record (2/9/2026). The subject matter of claim 6 would be allowable once the objection outlined above has been overcome. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EDT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 8/14/2026
Read full office action

Prosecution Timeline

Mar 01, 2024
Application Filed
Feb 09, 2026
Non-Final Rejection mailed — §112
Jul 09, 2026
Response after Non-Final Action
Jul 09, 2026
Response Filed
Aug 05, 2026
Response Filed
Aug 18, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747253
KRAS G12D INHIBITORS
3y 8m to grant Granted Sep 29, 2026
Patent 12746193
COSMETIC COMPOSITION
2y 9m to grant Granted Sep 29, 2026
Patent 12746293
DNA Vector Delivery Using Lipid Nanoparticles
2y 10m to grant Granted Sep 29, 2026
Patent 12746263
COMPOSITION FOR TREATMENT OF AUTOIMMUNE DISEASES COMPRISING LACTOBACILLUS SAKEI OR EXTRACELLULAR VESICLES DERIVED THEREFROM AS ACTIVE INGREDIENT
2y 9m to grant Granted Sep 29, 2026
Patent 12746278
COMPOSITIONS AND METHODS FOR WOUND HEALING
2y 3m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
85%
Grant Probability
81%
With Interview (-4.0%)
1y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1589 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month